SUPERNUS PHARMS
SpecialtySUPERNUS PHARMS is a specialty pharmaceutical company focused on Neurology, Dermatology. Key products include TROKENDI XR.
FDA Novel Drug Designations
(2021)See 1 novel approval →
SUPERNUS PHARMS at a Glance
- Fast trial execution (14 months median completion)
SUPERNUS PHARMS's Key Drugs
SUPERNUS PHARMS's core commercial portfolio centers on TROKENDI XR, GOCOVRI, OXTELLAR XR, spanning Neurology and Dermatology — its most strategically important drugs approved in the last 15 years.
SUPERNUS PHARMS's Recent FDA Approvals
New NDA/BLA approvals for SUPERNUS PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
SUPERNUS PHARMS's Therapeutic Areas
SUPERNUS PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Dermatology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SUPERNUS PHARMS's Top Competitors
SUPERNUS PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and PAI HOLDINGS PHARM. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SUPERNUS PHARMS Pipeline Snapshot
Active clinical trials for SUPERNUS PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 14/19 completed
- • Speed: 14 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (1)
Company Info
- First Approval
- 2012-10-19
- Latest
- 2026-03-06
- Applications
- 5
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges